AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS

Late-breaking Hot Line Oral Presentation on FOURIER-OLE Data Represents Longest Trials of a PCSK9i to Date New HEYMANS, HAUSER Data to be Presented THOUSAND OAKS, Calif., Aug. 22, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV)…